Maternal fructose intake modulates cholesterol metabolism in response to a western diet in the offspring

Q Pharmacology, Toxicology and Pharmaceutics Anales De La Real Academia Nacional De Farmacia Pub Date : 2022-10-10 DOI:10.53519/analesranf.2022.88.03.01
Paloma López Laiz, E. Fauste, M. Panadero, C. Donis, P. Otero, Carlos coaut. Bocos de Prada
{"title":"Maternal fructose intake modulates cholesterol metabolism in response to a western diet in the offspring","authors":"Paloma López Laiz, E. Fauste, M. Panadero, C. Donis, P. Otero, Carlos coaut. Bocos de Prada","doi":"10.53519/analesranf.2022.88.03.01","DOIUrl":null,"url":null,"abstract":"Fructose consumption has increased during the last decades, while a simultaneous rise in the incidence of pathologies such as type 2 diabetes and metabolic syndrome has also taken place. Although there is evidence that fructose can cause alterations in the offspring related to the development of the aforementioned diseases, exposure to fructose during pregnancy is not contraindicated for women. This effect is explained by the concept of foetal programming, which suggests that changes that occur during the embryogenic and foetal stages are permanent in the adult, due to maternal health, diet and other environmental factors.\nTherefore, the effect of fructose on cholesterol metabolism in the offspring of mothers fed with or without fructose during gestation was studied. In addition, the progeny also received different diets: fructose (with and without supplementation of cholesterol) or tagatose solutions.\nTagatose increased non-HDL cholesterol in the offspring of water-fed mothers, whereas fructose consumption during gestation dampened this effect, indicating foetal programming. In addition, fructose and tagatose feeding increased atherogenic indices by decreasing HDL-cholesterol concentration and increasing triglycerides levels.\nOn the other hand, the addition of cholesterol to fructose consumption caused an increase in total cholesterol and a change in its distribution: higher concentration of non-HDL cholesterol and lower concentration of HDL cholesterol, independently of maternal feeding. This also caused an increase in atherogenic indices.\nUltimately, the results indicate that cholesterol metabolism is influenced by both maternal fructose consumption, and the subsequent intake of fructose (alone or in combination with cholesterol) and tagatose in the offspring.","PeriodicalId":50795,"journal":{"name":"Anales De La Real Academia Nacional De Farmacia","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anales De La Real Academia Nacional De Farmacia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53519/analesranf.2022.88.03.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Fructose consumption has increased during the last decades, while a simultaneous rise in the incidence of pathologies such as type 2 diabetes and metabolic syndrome has also taken place. Although there is evidence that fructose can cause alterations in the offspring related to the development of the aforementioned diseases, exposure to fructose during pregnancy is not contraindicated for women. This effect is explained by the concept of foetal programming, which suggests that changes that occur during the embryogenic and foetal stages are permanent in the adult, due to maternal health, diet and other environmental factors. Therefore, the effect of fructose on cholesterol metabolism in the offspring of mothers fed with or without fructose during gestation was studied. In addition, the progeny also received different diets: fructose (with and without supplementation of cholesterol) or tagatose solutions. Tagatose increased non-HDL cholesterol in the offspring of water-fed mothers, whereas fructose consumption during gestation dampened this effect, indicating foetal programming. In addition, fructose and tagatose feeding increased atherogenic indices by decreasing HDL-cholesterol concentration and increasing triglycerides levels. On the other hand, the addition of cholesterol to fructose consumption caused an increase in total cholesterol and a change in its distribution: higher concentration of non-HDL cholesterol and lower concentration of HDL cholesterol, independently of maternal feeding. This also caused an increase in atherogenic indices. Ultimately, the results indicate that cholesterol metabolism is influenced by both maternal fructose consumption, and the subsequent intake of fructose (alone or in combination with cholesterol) and tagatose in the offspring.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
母体果糖摄入调节后代对西方饮食的胆固醇代谢
在过去的几十年里,果糖的消耗量增加了,与此同时,2型糖尿病和代谢综合征等疾病的发病率也在上升。尽管有证据表明果糖会导致与上述疾病发展相关的后代发生改变,但在怀孕期间接触果糖并不是女性的禁忌。胎儿编程概念解释了这种影响,该概念表明,由于产妇健康、饮食和其他环境因素,胚胎期和胎儿期发生的变化在成年后是永久性的。因此,研究了果糖对妊娠期间喂食或不喂食果糖的母鼠后代胆固醇代谢的影响。此外,后代也接受了不同的饮食:果糖(有或没有补充胆固醇)或塔格糖溶液。塔格糖增加了水喂养的母亲的后代的非高密度脂蛋白胆固醇,而妊娠期间摄入果糖则抑制了这种影响,表明胎儿编程。此外,果糖和塔格糖喂养通过降低hdl -胆固醇浓度和增加甘油三酯水平增加动脉粥样硬化指数。另一方面,在摄入果糖的同时增加胆固醇,导致总胆固醇升高,并改变其分布:非高密度脂蛋白胆固醇浓度升高,高密度脂蛋白胆固醇浓度降低,与母体喂养无关。这也导致了动脉粥样硬化指数的增加。最终,研究结果表明,胆固醇代谢受到母体果糖消耗以及后代随后摄入果糖(单独或与胆固醇结合)和塔格糖的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.13
自引率
0.00%
发文量
7
期刊介绍: The Anales de la Real Academia Nacional de Farmacia� embraces all aspects of pharmaceutical sciences and is a quarterly journal that publishes basic and applied research on pharmaceutical sciences and related areas. It is a medium for reporting selected original and significant contributions to new pharmaceutical knowledge.
期刊最新文献
Therapeutic repositioning: importance of new therapeutic indications approved for old medicines The mRNA COVID 19 vaccine: More than a drug? Detection and management of a case of drug-resistant hypertension Galenic development of a capsule containing rosuvastatin, repaglinide, and olmesartan mini-tablets for the treatment of metabolic syndrome Novel drugs recently authorized by ema and fda (Q2, 2024)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1